Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5399493

Title:Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
Inventors:Emerson, Stephen G.; Ann Arbor, MI, USA
Clarke, Michael F.; Ann Arbor, MI, USA
Palsson, Bernhard O.; Ann Arbor, MI, USA
Schwartz, Richard M.; Ann Arbor, MI, USA
Summary:Described herein are methods and compositions for optimizing human hematopoietic progenitor cell cultures. The invention relates to a process by which human stem cells are cultured with a high medium exchange rate that allows for the simultaneous removal of metabolic byproducts and the replenishing of depleted nutrients. Further disclosed are conditions for the ex vivo optimization of human stem cell division and the stable genetic transformation of human hematopoietic progenitor cell cultures in which the metabolism, and GM-CSF secretion or IL-6 secretion of human stromal cells is increased. Also provided are methods by which a liquid culture medium which is preferably perfused, either continuously or periodically, so that metabolic byproducts are removed and depleted nutrients are replenished while the culture is maintained under physiologically acceptable conditions in the presence of growth factors. This invention represents a continuation of other applications filed by the same assignee and inventors.
Abstract:Methods, including culture media conditions, which provide for ex vivo human stem cell division and stable genetic transformation and/or the optimization of human hematopoietic progenitor cell cultures and/or increasing the metabolism or GM-CSF secretion or IL-6 secretion of human stromal cells are disclosed. The methods rely on culturing human stem cells and/or human hematopoietic progenitor cells and/or human stromal cells in a liquid culture medium which is replaced, preferably perfused, either continuously or periodically, at a rate of 1 ml of medium per ml of culture per about 24 to about 48 hour period, and removing metabolic products and replenishing depleted nutrients while maintaining the culture under physiologically acceptable conditions. Optionally growth factors are added to the culture medium.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5399493
Application Number:US1991000740590
Date Filed:05/08/1991
Date Published:21/03/1995
Assignee:The Regents of the University of Michigan, Ann Arbor, MI, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/22/2021